Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (3582)	12/29/2000 10:59:36 AM
From: Eric Fader	Read Replies (3) \| Respond to of 5582

Dan - if that were true, the trades should have been coded on the time and sales report as you know. MMs get fined for this oversight (or deception), so I doubt that's what happened. I don't disagree, however, that there may be possible explanations other than those I posted. Again, I'm most curious about the source of the stock, rather than the buyers. More blocks printed this morning at the 6-3/4 offer. -Eric

To: DanZ who wrote (3582)	12/29/2000 11:22:27 AM
From: Mark Marcellus	Respond to of 5582

Who is Zengen? Interesting question. Here's what a few minutes of internet research reveals: - They are located about 2 blocks from Gel Tech's offices. - They are not a reporting company but have an "investor relations" tab on their web page. "Financial information" is available on request. - They are somehow associated with a company called Biotem Cytotechnologies. This company was in turn somehow involved in clinical studies regarding a product called Actisys which is marketed by a company called SportPharma USA. I have no idea whether there was any involvement of Biotem with SportPharma other than the study. SportPharma was spanked by a US District court for making false advertising claims for Actisys: universal-zone.com The company portrayed this ruling as a victory: findarticles.com I also have no idea as to Biotem's involvement, if any, with the advertising claims which got SportPharma in hot water. I mention this association because 1) it was about all I could find on Biotem and 2) it does indicate that we are not dealing with the top tier of that drug/biotech sector which Dan is so proud to be a part of. Could someone open a window? It's starting to get a little smelly in here again.

To: DanZ who wrote (3582)	12/29/2000 11:31:17 AM
From: rli123	Respond to of 5582

Dan --- from the Zengen website (Zengen.com), see the bio for Charles Hensley. It appears that Biodelivery Tech was ACQUIRED by Zengen in March 2000!! I thought GUMM had the right to purchase the remaining 40% of Gel Tech that it doesn't already own --- maybe it'll have to be purchased from Zengen, the new owner of BDT. rli Charles B. Hensley, Ph.D. President, Director Dr. Hensley has been President and a Director of Zengen since October 1999. Prior to joining Zengen, Dr. Hensley was Chief of Research and Scientific Affairs at Gel Tech, LLC, a joint venture between Biodelivery Technologies, Inc., and Gum Tech International, a Nasdaq publicly traded company. From 1997 to 1999, Dr. Hensley served as Chairman of Biodelivery Technologies, Inc., which was acquired by Zengen in March 2000. From 1994 to 1997, Dr. Hensley served as Chairman of Biotem Cytotechnologies, a research company specializing in natural therapeutics. Dr. Hensley received his bachelor's of science degree in Zoology from the University of Oklahoma. Dr. Hensley received his Ph. D. in Physiology and Biophysics from the University of Southern California and served his postdoctoral fellowship at the University of Southern California where he specialized in the regulation of gene expression in the myocardium. Dr. Hensley has held various teaching positions at University of Southern California and University of California, Riverside.